Recent advances in histone deacetylase targeted cancer therapy

Surgery Today

Volumn 40, Issue 9, 2010, Pages 809-815

  Hoshino, Isamu ^a   Matsubara, Hisahiro ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Cancer therapy; Histone deacetylase inhibitor; Molecular targeted therapy

Indexed keywords

4 N ACETYLDINALINE; ARYLBUTYRIC ACID DERIVATIVE; BUTYRIC ACID; CISPLATIN; CYCLIC HYDROXAMIC ACID CONTAINING PEPTIDE 31; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDRALAZINE; ISTODAX; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; RETINOIC ACID; ROMIDEPSIN; TRAPOXIN B; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ABDOMINAL PAIN; ADD ON THERAPY; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN CANCER; BREAST CANCER; CANCER THERAPY; CELLULITIS; CLINICAL TRIAL; COLON CANCER; CONFUSION; CONTINUOUS INFUSION; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DISORIENTATION; DIZZINESS; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; ENZYME ACTIVITY; EPIGENETICS; ESOPHAGUS CANCER; EWING SARCOMA; FATIGUE; FIBROSARCOMA; GENE TARGETING; GLIOBLASTOMA; HEART ARRHYTHMIA; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOXIA; LEUKEMIA; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHOMA; MELANOMA; METABOLIC DISORDER; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PROCTITIS; PROSTATE CANCER; RECOMMENDED DRUG DOSE; RECTUM CANCER; RECTUM CARCINOMA; REVIEW; SARCOMA; SOLID TUMOR; SOMNOLENCE; STOMACH CANCER; THROMBOCYTOPENIA; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; VEIN THROMBOSIS; VOMITING;

ANTINEOPLASTIC AGENTS; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 77956898565     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-010-4300-6     Document Type: Review

References (78)

1. A. Risch C. Plass 2008 Lung cancer epigenetics and genetics Int J Cancer 123 1 7 10.1002/ijc.23605 18425819 (Pubitemid 351705185)
2. L.B. Koppert B.P. Wijnhoven H. van Dekken H.W. Tilanus W.N. Dinjens 2005 The molecular biology of esophageal adenocarcinoma J Surg Oncol 92 169 190 10.1002/jso.20359 16299787 (Pubitemid 41779299)
3. H.C. Pitot H. Hikita Y. Dragan M. Haas 2000 Review article: the stages of gastrointestinal carcinogenesis-application of rodent models to human disease Aliment Pharmacol Ther 14 suppl1 153 160 10.1046/j.1365-2036.2000.014s1153.x 10807417
4. I.A. Lea M.A. Jackson X. Li S. Bailey S.D. Peddada J.K. Dunnick 2007 Genetic pathways and mutation profiles of human cancers: site- and exposure-specific patterns Carcinogenesis 28 1851 1858 10.1093/carcin/bgm176 17693665 (Pubitemid 47504878)
5. A.O. Chan A. Rashid 2006 CpG island methylation in precursors of gastrointestinal malignancies Curr Mol Med 6 4 401 408 10.2174/ 156652406777435417 16900663 (Pubitemid 43834253)
6. L. Kopelovich J.A. Crowell J.R. Fay 2003 The epigenome as a target for cancer chemoprevention J Natl Cancer Inst 95 23 1747 1757 14652236
7. G.J. Narlikar H.Y. Fan R.E. Kingston 2002 Cooperation between complexes that regulate chromatin structure and transcription Cell 108 4 475 487 10.1016/S0092-8674(02)00654-2 11909519 (Pubitemid 34260873)
8. L. Lafon-Hughes M.V. Di Tomaso L. Méndez-Acuña W. Martínez-López 2008 Chromatin-remodelling mechanisms in cancer Mutat Res 658 3 191 214 10.1016/j.mrrev.2008.01.008 18403253
9. S. Minucci P.G. Pelicci 2006 Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer Nat Rev Cancer 6 1 38 51 10.1038/nrc1779 16397526 (Pubitemid 43054973)
10. M. Toyota J.P. Issa 2005 Epigenetic changes in solid and hematopoietic tumors Semin Oncol 32 5 521 530 10.1053/j.seminoncol.2005.07.003 16210093 (Pubitemid 41396429)
11. P. Gallinari S. Di Marco P. Jones M. Pallaoro C. Steinkühler 2007 HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics Cell Res 17 3 195 211 17325692
12. H. Enokida M. Nakagawa 2008 Epigenetics in bladder cancer Int J Clin Oncol 13 4 298 307 10.1007/s10147-008-0811-1 18704629
13. K. Kanao S. Mikami R. Mizuno T. Shinojima M. Murai M. Oya 2008 Decreased acetylation of histone H3 in renal cell carcinoma: a potential target of histone deacetylase inhibitors J Urol 180 3 1131 1136 10.1016/j.juro.2008.04.136 18639283
14. L. Ellis Y. Pan G.K. Smyth D.J. George C. McCormack R. Williams-Truax, et al. 2008 Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma Clin Cancer Res 14 14 4500 4510 10.1158/1078-0432.CCR-07-4262 18628465
15. I. Hoshino H. Matsubara Y. Akutsu T. Nishimori Y. Yoneyama K. Murakami, et al. 2007 Gene expression profiling induced by histone deacetylase inhibitor, FK228, in human esophageal squamous cancer cells Oncol Rep 18 3 585 592 17671705
16. H. Yamada Y. Arakawa S. Saito M. Agawa Y. Kano J. Horiguchi-Yamada 2006 Depsipeptide-resistant KU812 cells show reversible P-glycoprotein expression, hyper-acetylated histones, and modulated gene expression profile Leuk Res 30 6 723 734 10.1016/j.leukres.2005.09.014 16260035
17. J. Joseph G. Mudduluru S. Antony S. Vashistha P. Ajitkumar K. Somasundaram 2004 Expression profiling of sodium butyrate (NaB)-treated cells: identification of regulation of genes related to cytokine signaling and cancer metastasis by NaB Oncogene 23 37 6304 6315 10.1038/sj.onc.1207852 15318170 (Pubitemid 39215301)
18. J. Sonnemann L. Dreyer M. Hartwig C.D. Palani T.T. Hongle U. Klier, et al. 2007 Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing's sarcoma cells J Cancer Res Clin Oncol 133 11 847 858 10.1007/s00432-007-0227-8 17486365 (Pubitemid 350218911)
19. K. Ogawa S. Yasumura Y. Atarashi M. Minemura T. Miyazaki M. Iwamoto, et al. 2004 Sodium butyrate enhances Fas-mediated apoptosis of human hepatoma cells J Hepatol 40 2 278 284 10.1016/j.jhep.2003.09.021 14739099 (Pubitemid 38115833)
20. S. Nakata T. Yoshida M. Horinaka T. Shiraishi M. Wakada T. Sakai 2004 Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells Oncogene 23 37 6261 671 10.1038/sj.onc.1207830 15208660 (Pubitemid 39215296)
21. A.A. Ruefli M.J. Ausserlechner D. Bernhard V.R. Sutton K.M. Tainton R. Kofler, et al. 2001 The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species Proc Natl Acad Sci USA 98 19 10833 10838 10.1073/pnas.191208598 11535817 (Pubitemid 32878706)
22. D. Bandyopadhyay A. Mishra E.E. Medrano 2004 Overexpression of histone deacetylase 1 confers resistance to sodium butyrate-mediated apoptosis in melanoma cells through a p53-mediated pathway Cancer Res 64 21 7706 7710 10.1158/0008-5472.CAN-03-3897 15520174 (Pubitemid 39446901)
23. A.J. Wilson D.S. Byun N. Popova L.B. Murray K. L'Italien Y. Sowa, et al. 2006 Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer J Biol Chem 281 13548 13558 10.1074/jbc.M510023200 16533812 (Pubitemid 43855268)
24. M. Nakagawa Y. Oda T. Eguchi S. Aishima T. Yao F. Hosoi, et al. 2007 Expression profile of class I histone deacetylases in human cancer tissues Oncol Rep 18 769 774 17786334
25. K. Ishihama M. Yamakawa S. Semba H. Takeda S. Kawata S. Kimura, et al. 2007 Expression of HDAC1 and CBP/p300 in human colorectal carcinomas J Clin Pathol 60 1205 1210 10.1136/jcp.2005.029165 17720775 (Pubitemid 350084539)
26. P. Zhu E. Martin J. Mengwasser P. Schlag K.P. Janssen M. Gottlicher 2004 Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis Cancer Cell 5 455 463 10.1016/S1535-6108(04)00114-X 15144953 (Pubitemid 38610247)
27. C.A. Krusche A.J. Vloet I. Classen-Linke U. von Rango H.M. Beier J. Alfer 2007 Class I histone deacetylase expression in the human cyclic endometrium and endometrial adenocarcinomas Hum Reprod 22 11 2956 2966 10.1093/humrep/dem241 17728353 (Pubitemid 351696801)
28. W. Weichert A. Röske V. Gekeler T. Beckers M.P. Ebert M. Pross, et al. 2008 Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis Lancet Oncol 9 2 139 148 10.1016/S1470-2045(08)70004-4 18207460
29. Y. Toh T. Ohga K. Endo E. Adachi H. Kusumoto M. Haraguchi, et al. 2004 Expression of the metastasis-associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas Int J Cancer 110 362 367 10.1002/ijc.20154 15095300 (Pubitemid 38649886)
30. Y. Toh S. Kuninaka K. Endo T. Oshiro Y. Ikeda H. Nakashima, et al. 2000 Molecular analysis of a candidate metastasis-associated gene, MTA1: possible interaction with histone deacetylase 1 J Exp Clin Cancer Res 19 105 111 10840944
31. J. Taunton C.A. Hassig S.L. Schreiber 1996 A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p Science 272 5260 408 411 10.1126/science.272.5260.408 8602529
32. P.A. Marks V.M. Richon T. Miller W.K. Kelly 2004 Histone deacetylase inhibitors Adv Cancer Res 91 137 168 10.1016/S0065-230X(04)91004-4 15327890 (Pubitemid 39140958)
33. S.G. Gray T.J. Ekström 2001 The human histone deacetylase family Exp Cell Res 262 2 75 83 10.1006/excr.2000.5080 11139331 (Pubitemid 32980246)
34. E. Verdin F. Dequiedt H.G. Kasler 2003 Class II histone deacetylases: versatile regulators Trends Genet 19 5 286 293 10.1016/S0168-9525(03)00073-8 12711221 (Pubitemid 36507011)
35. A. Mai S. Massa R. Pezzi S. Simeoni D. Rotili A. Nebbioso, et al. 2005 Class II (IIa)-selective histone deacetylase inhibitors. 1. Synthesis and biological evaluation of novel (aryloxopropenyl)pyrrolyl hydroxyamides J Med Chem 48 9 3344 3353 10.1021/jm049002a 15857140 (Pubitemid 40628053)
36. T. Sjöblom S. Jones L.D. Wood D.W. Parsons J. Lin T.D. Barber, et al. 2006 The consensus coding sequences of human breast and colorectal cancers Science 314 5797 268 274 10.1126/science.1133427 16959974 (Pubitemid 44571966)
37. C. Friend W. Scher J.G. Holland T. Sato 1971 Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide Proc Natl Acad Sci USA 68 2 378 382 5277089
38. D.C. Drummond C.O. Noble D.B. Kirpotin Z. Guo G.K. Scott C.C. Benz 2005 Clinical development of histone deacetylase inhibitors as anticancer agents Annu Rev Pharmacol Toxicol 45 495 528 10.1146/annurev.pharmtox.45.120403.095825 15822187 (Pubitemid 40261815)
39. S.Y. Archer S. Meng A. Shei R.A. Hodin 1998 p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells Proc Natl Acad Sci USA 95 12 6791 6796 10.1073/pnas.95.12.6791 9618491 (Pubitemid 28278059)
40. B.A. Conley M.J. Egorin N. Tait D.M. Rosen E.A. Sausville G. Dover, et al. 1998 Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors Clin Cancer Res 4 3 629 634 9533530
41. M.J. Edelman K. Bauer S. Khanwani N. Tait J. Trepel J. Karp, et al. 2003 Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug Cancer Chemother Pharmacol 51 5 439 444 12736763
42. M. Entin-Meer A. Rephaeli X. Yang A. Nudelman S.R. VandenBerg D.A. Haas-Kogan 2005 Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas Mol Cancer Ther 4 12 1952 1961 10.1158/1535-7163.MCT-05-0087 16373710 (Pubitemid 43056978)
43. W.K. Kelly O.A. O'Connor P.A. Marks 2002 Histone deacetylase inhibitors: from target to clinical trials Expert Opin Invest Drugs 11 12 1695 1713 10.1517/13543784.11.12.1695 (Pubitemid 35469917)
44. M.R. Acharya A. Sparreboom J. Venitz W.D. Figg 2005 Rational development of histone deacetylase inhibitors as anticancer agents: a review Mol Pharmacol 68 4 917 932 10.1124/mol.105.014167 15955865 (Pubitemid 41345783)
45. J.L. Tischler B. Abuaita S.C. Cuthpert C. Fage K. Murphy A. Saxe, et al. 2008 Simple inhibitors of histone deacetylase activity that combine features of short-chain fatty acid and hydroxamic acid inhibitors J Enzyme Inhib Med Chem 23 4 549 555 10.1080/14756360701715703 18608778
46. H.Y. Lin C.S. Chen S.P. Lin J.R. Weng C.S. Chen 2006 Targeting histone deacetylase in cancer therapy Med Res Rev 26 4 397 413 10.1002/med.20056 16450343 (Pubitemid 43939200)
47. M. Kijima M. Yoshida K. Sugita S. Horinouchi T. Beppu 1993 Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase J Biol Chem 268 30 22429 22435 8226751
48. P.A. Marks V.M. Richon R.A. Rifkind 2000 Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells J Natl Cancer Inst 92 15 1210 1216 10.1093/jnci/92.15.1210 10922406
49. P.H. Kuo K.R. Carlson I. Christensen M. Girardi P.W. Heald 2008 FDG-PET/CT for the evaluation of response to therapy of cutaneous T-cell lymphoma to Vorinostat (suberoylanilide hydroxamic acid, SAHA) in a phase II trial Mol Imaging Biol 10 6 306 314 10.1007/s11307-008-0161-4 18665425
50. S.C. Modesitt M. Sill J.S. Hoffman D.P. Bender Gynecologic Oncology Group 2008 A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 109 2 182 186 10.1016/j.ygyno.2008.01.009 18295319
51. I. Hoshino H. Matsubara N. Hanari M. Mori T. Nishimori Y. Yoneyama, et al. 2005 Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells Clin Cancer Res 11 21 7945 7952 10.1158/1078-0432.CCR-05-0840 16278420 (Pubitemid 41611642)
52. J. Hong K. Ishihara K. Yamaki K. Hiraizumi T. Ohno J.W. Ahn, et al. 2003 Apicidin, a histone deacetylase inhibitor, induces differentiation of HL-60 cells Cancer Lett 189 2 197 206 10.1016/S0304-3835(02)00500-1 12490313 (Pubitemid 35461996)
53. H. Ueda H. Nakajima Y. Hori T. Fujita M. Nishimura T. Goto, et al. 1994 FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity J Antibiot (Tokyo) 47 3 301 310
54. R. Furumai A. Matsuyama N. Kobashi K.H. Lee M. Nishiyama H. Nakajima, et al. 2002 FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases Cancer Res 62 17 4916 4921 12208741
55. I. Hoshino H. Matsubara Y. Akutsu T. Nishimori Y. Yoneyama K. Murakami, et al. 2008 Role of histone deacetylase inhibitor in adenovirus-mediated p53 gene therapy in esophageal cancer Anticancer Res 28 2A 665 671 18507005
56. D.S. Schrump M.R. Fischette D.M. Nguyen M. Zhao X. Li T.F. Kunst, et al. 2008 Clinical and molecular responses in lung cancer patients receiving Romidepsin Clin Cancer Res 14 1 188 198 10.1158/1078-0432.CCR-07-0135 18172270 (Pubitemid 351377995)
57. W.M. Stadler K. Margolin S. Ferber W. McCulloch J.A. Thompson 2006 A phase II study of depsipeptide in refractory metastatic renal cell cancer Clin Genitourin Cancer 5 1 57 60 10.3816/CGC.2006.n.018 16859580
58. T. Suzuki T. Ando K. Tsuchiya N. Fukazawa A. Saito Y. Mariko, et al. 1999 Synthesis and histone deacetylase inhibitory activity of new benzamide derivatives J Med Chem 42 15 3001 3003 10.1021/jm980565u 10425110 (Pubitemid 29370445)
59. M.R. Acharya A. Sparreboom J. Venitz W.D. Figg 2005 Rational development of histone deacetylase inhibitors as anticancer agents: a review Mol Pharmacol 68 4 917 932 10.1124/mol.105.014167 15955865 (Pubitemid 41345783)
60. Q.C. Ryan D. Headlee M. Acharya A. Sparreboom J.B. Trepel J. Ye, et al. 2005 Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma J Clin Oncol 23 17 3912 3922 10.1200/JCO.2005.02.188 15851766 (Pubitemid 46218694)
61. M.R. Acharya J.E. Karp E.A. Sausville K. Hwang Q. Ryan I. Gojo, et al. 2006 Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer Invest New Drugs 24 5 367 375 10.1007/s10637-005-5707-6 16583304 (Pubitemid 43876072)
62. M. Yoshida S. Horinouchi T. Beppu 1995 Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function Bioessays 17 5 423 430 10.1002/bies.950170510 7786288
63. M. Kijima M. Yoshida K. Sugita S. Horinouchi T. Beppu 1993 Trapoxin, an antitumor cyclic tetrapeptide, is an irreversible inhibitor of mammalian histone deacetylase J Biol Chem 268 30 22429 22435 8226751
64. H. Yoshida K. Sugita 1992 A novel tetracyclic peptide, trapoxin, induces phenotypic change from transformed to normal in sis-oncogenetransformed NIH3T3 cells Jpn J Cancer Res 83 4 324 328 1506265
65. R. Furumai Y. Komatsu N. Nishino S. Khochbin M. Yoshida S. Horinouchi 2001 Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin Proc Natl Acad Sci USA 98 1 87 92 10.1073/pnas.011405598 11134513 (Pubitemid 32095868)
66. Y. Komatsu K.Y. Tomizaki M. Tsukamoto T. Kato N. Nishino S. Sato, et al. 2001 Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity Cancer Res 61 11 4459 4466 11389076
67. K. Taura Y. Yamamoto A. Nakajima K. Hata H. Uchinami K. Yonezawa, et al. 2004 Impact of novel histone deacetylase inhibitors, CHAP31 and FR901228 (FK228), on adenovirus-mediated transgene expression J Gene Med 6 5 526 536 10.1002/jgm.546 15133763 (Pubitemid 40228068)
68. A. Chavez-Blanco B. Segura-Pacheco E. Perez-Cardenas L. Taja-Chayeb L. Cetina M. Candelaria, et al. 2005 Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study Mol Cancer 4 1 22 10.1186/1476-4598-4-22 16001982 (Pubitemid 41460837)
69. A. Atmaca S.E. Al-Batran A. Maurer A. Neumann T. Heinzel B. Hentsch, et al. 2007 Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial Br J Cancer 97 2 177 182 10.1038/sj.bjc. 6603851 17579623 (Pubitemid 47057472)
70. A. Duenas-Gonzalez M. Candelaria C. Perez-Plascencia E. Perez-Cardenas E. de la Cruz-Hernandez L.A. Herrera 2008 Valproic acid as epigenetic cancer drug: preclinical, clinical and transcriptional effects on solid tumors Cancer Treat Rev 34 3 206 222 10.1016/j.ctrv.2007.11.003 18226465
71. I. Gojo A. Jiemjit J.B. Trepel A. Sparreboom W.D. Figg S. Rollins, et al. 2007 Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias Blood 109 7 2781 2790 17179232
72. Q.C. Ryan D. Headlee M. Acharya A. Sparreboom J.B. Trepel J. Ye, et al. 2005 Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma J Clin Oncol 23 17 3912 3922 10.1200/JCO.2005.02.188 15851766 (Pubitemid 46218694)
73. L. Gore S. Holden M. Basche S. Raj I. Arnold C. O'Bryant, et al. 2004 Updated results from a phase I trial of the histone deacetylase inhibitor MS-275 in patients with refractory solid tumors J Clin Oncol 22 14S 3026
74. A. Hauschild U. Trefzer C. Garbe K.C. Kaehler S. Ugurel F. Kiecker, et al. 2006 A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma J Clin Oncol 24 18S 8044
75. R. Pili M. Rudek S. Altiok D. Qian M. Zhao R. Donehower, et al. 2006 Phase I pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor MS-275 in combination with 13-cis-retinoic acid in patients with advanced solid tumors J Clin Oncol 24 18S 3055
76. R.L. Piekarz R. Robey V. Sandor S. Bakke W.H. Wilson L. Dahmoush, et al. 2001 Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report Blood 98 9 2865 2868 10.1182/blood.V98.9.2865 11675364
77. V. Sandor S. Bakke R.W. Robey M.H. Kang M.V. Blagosklonny J. Bender, et al. 2002 Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms Clin Cancer Res 8 3 718 728 11895901
78. D.S. Schrump M.R. Fischette D.M. Nguyen M. Zhao X. Li T.F. Kunst, et al. 2008 Clinical and molecular responses in lung cancer patients receiving Romidepsin Clin Cancer Res 14 1 188 198 10.1158/1078-0432.CCR-07-0135 18172270 (Pubitemid 351377995)